However, after a re-evaluation on 27 February 2025, the CHMP upheld its initial stance, stating that the committee’s concerns ...

1 "The CHMP's positive opinion for upadacitinib for adults living with giant cell arteritis is an important step toward our goal of improving outcomes for patients suffering with this disease ...